NasdaqGS:AGIOBiotechs
A Look At Agios Pharmaceuticals (AGIO) Valuation After PYRUKYND Approval And GCC Expansion
Agios Pharmaceuticals (AGIO) is back in focus after the Emirates Drug Establishment approved PYRUKYND for adult thalassemia patients in the UAE, alongside a NewBridge Pharmaceuticals deal to expand access across the Gulf Cooperation Council.
See our latest analysis for Agios Pharmaceuticals.
The PYRUKYND approvals in the Gulf region arrive after a mixed run for investors, with a 4.19% 1 month share price return to US$28.07, contrasted against a 12.23% 1 year total shareholder return decline...